Literature DB >> 29948742

Appropriateness of vancomycin therapeutic drug monitoring and its outcomes among non-dialysis patients in a tertiary hospital in Singapore.

Jun Jie Benjamin Seng1, Mei Hui Amanda Yong2, Zi Xin Peh2, Jie Lin Soong2, Mooi Heong Tan2.   

Abstract

Background Vancomycin therapeutic drug monitoring (TDM) is commonly performed to ensure safe and effective use of the antibiotic. Aim of Study To evaluate appropriateness of vancomycin TDM and its outcomes in Singapore General Hospital. Method A retrospective, cross-sectional study was conducted between 1 January 2014 and 28 February 2014 involving patients who received ≥ 1 dose of intravenous vancomycin with TDM. Patient demographics and relevant vancomycin TDM data were collected from medical records. Results Of 746 vancomycin troughs measured among 234 patients, 459 troughs (61.5%) were taken inappropriately, with a median time of 2.6 h (interquartile range 1.1-4.3) before the next scheduled dose. Inappropriate interpretation of vancomycin troughs resulted in 41 unnecessary dose suspensions, 24 dose changes, and 102 unchanged vancomycin doses. The cost incurred due to inappropriate interpretation and measurement after discontinuation of treatment was US$7286. No differences in rates of vancomycin related nephrotoxicity, ototoxicity, recurrent infection, development of infection secondary to vancomycin resistant microorganism and mortality were observed (p > 0.05). Conclusion This study highlighted a high incidence of inappropriate vancomycin TDM which has led to increased healthcare cost.

Entities:  

Keywords:  Dosing; Outcomes; Singapore; Therapeutic drug monitoring; Timing; Vancomycin

Mesh:

Substances:

Year:  2018        PMID: 29948742     DOI: 10.1007/s11096-018-0670-4

Source DB:  PubMed          Journal:  Int J Clin Pharm


  10 in total

1.  High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures.

Authors:  F Pea; L Porreca; M Baraldo; M Furlanut
Journal:  J Antimicrob Chemother       Date:  2000-03       Impact factor: 5.790

2.  Effects of therapeutic drug monitoring criteria in a computerized prescriber-order-entry system on the appropriateness of vancomycin level orders.

Authors:  Kristi A Traugott; Pamela R Maxwell; Kay Green; Christopher Frei; James S Lewis
Journal:  Am J Health Syst Pharm       Date:  2011-02-15       Impact factor: 2.637

Review 3.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

Review 4.  Improving the use of therapeutic drug monitoring.

Authors:  D W Bates
Journal:  Ther Drug Monit       Date:  1998-10       Impact factor: 3.681

5.  Pharmacokinetics of vancomycin in patients with various degrees of renal function.

Authors:  G R Matzke; R W McGory; C E Halstenson; W F Keane
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

6.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 7.  Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections.

Authors:  Christopher Giuliano; Christopher Giulano; Krystal K Haase; Ronald Hall
Journal:  Expert Rev Anti Infect Ther       Date:  2010-01       Impact factor: 5.091

8.  Effect of education on the appropriateness of serum drug concentration determination.

Authors:  D J Carroll; G E Austin; G V Stajich; R K Miyahara; J E Murphy; E S Ward
Journal:  Ther Drug Monit       Date:  1992-02       Impact factor: 3.681

9.  Short term impact of guidelines on vancomycin dosing and therapeutic drug monitoring.

Authors:  Maria Swartling; Reetu Gupta; Vicky Dudas; B Joseph Guglielmo
Journal:  Int J Clin Pharm       Date:  2012-02-14

10.  Inappropriate vancomycin therapeutic drug monitoring in hospitalized pediatric patients increases pediatric trauma and hospital costs.

Authors:  Manika Suryadevara; Kelly E Steidl; Luke A Probst; Jana Shaw
Journal:  J Pediatr Pharmacol Ther       Date:  2012-04
  10 in total
  5 in total

1.  Vancomycin dosing and therapeutic drug monitoring practices: guidelines versus real-life.

Authors:  Tatjana Van Der Heggen; Franky M Buyle; Barbara Claus; Annemie Somers; Petra Schelstraete; Peter De Paepe; Sophie Vanhaesebrouck; Pieter A J G De Cock
Journal:  Int J Clin Pharm       Date:  2021-04-28

2.  Vancomycin pharmacokinetics in critically ill neonates receiving extracorporeal membrane oxygenation.

Authors:  Sook Hee An; Eun Mi Lee; Jae Yeon Kim; Hye Sun Gwak
Journal:  Eur J Hosp Pharm       Date:  2019-02-20

3.  Long-term vancomycin use had low risk of ototoxicity.

Authors:  Clayton Humphrey; Michael P Veve; Brian Walker; Mahmoud A Shorman
Journal:  PLoS One       Date:  2019-11-06       Impact factor: 3.240

4.  Evaluation of aminoglycosides utilization in intensive care units of a teaching hospital in southern Iran.

Authors:  Afsaneh Vazin; Mahtabalsadat Mirjalili; Sara Asadi
Journal:  Pharm Pract (Granada)       Date:  2019-09-17

5.  Relationship Between Mean Vancomycin Trough Concentration and Mortality in Critically Ill Patients: A Multicenter Retrospective Study.

Authors:  Yanli Hou; Jiajia Ren; Jiamei Li; Xuting Jin; Ya Gao; Ruohan Li; Jingjing Zhang; Xiaochuang Wang; Xinyu Li; Gang Wang
Journal:  Front Pharmacol       Date:  2021-07-19       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.